FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201612254> ?p ?o ?g. }

• W3201612254 endingPage "499" @default.
• W3201612254 startingPage "490" @default.
• W3201612254 abstract "Bevacizumab has an important and evolving role in improving outcomes in patients with metastatic colorectal cancer (mCRC) worldwide and was approved in China in 2010. However, there are limited real-world data on the efficacy and safety of chemotherapy regimens combined with bevacizumab in Chinese patients with mCRC. This observational, phase IV trial study aimed to obtain more experience on the efficacy and safety of bevacizumab combined with chemotherapy in Chinese mCRC patients.Between September 2013 and November 2016, patients with histologically confirmed mCRC were enrolled in a prospective, multicenter, observational, non-interventional phase IV trial at 26 centers across China. Eligible patients received different chemotherapeutic regimens combined with bevacizumab. The efficacy and safety data in the intention-to-treat study population were analyzed.A total of 611 patients were included in the efficacy analysis. The median overall survival and median progression-free survival was 18.00 and 10.05 months, respectively. The objective response rate was 21.00% and disease control rate was 89.40%. In subgroup analyses, the survival differences were observed according to metastatic status, duration of treatment and elevation in blood pressure. A total of 613 patients were evaluable for safety assessments. And 569 (92.82%) patients reported at least one adverse event (AE), and 151 (24.63%) experienced grade 3 or higher AEs. The incidence of bevacizumab-associated AEs of special interest was reported in 31 (5.06%) patients with hypertension (n=12), abscesses and fistulae (n=7), bleeding (n=6), proteinuria (n=3), gastrointestinal perforation (n=2) and venous thrombotic events (n=1).This observational phase IV trial broadens our experience and knowledge of bevacizumab in the Chinese population and provides a good indication of its overall efficacy and safety. Bevacizumab in combination with chemotherapy offers clinical benefits to Chinese patients with mCRC and has an acceptable and manageable safety profile." @default.
• W3201612254 created "2021-09-27" @default.
• W3201612254 creator A5001864411 @default.
• W3201612254 creator A5006423482 @default.
• W3201612254 creator A5012853410 @default.
• W3201612254 creator A5018806880 @default.
• W3201612254 creator A5019246084 @default.
• W3201612254 creator A5038522283 @default.
• W3201612254 creator A5046597133 @default.
• W3201612254 creator A5051014138 @default.
• W3201612254 creator A5053506947 @default.
• W3201612254 creator A5058194639 @default.
• W3201612254 creator A5060856715 @default.
• W3201612254 creator A5063077563 @default.
• W3201612254 creator A5067643729 @default.
• W3201612254 creator A5071654004 @default.
• W3201612254 creator A5072727640 @default.
• W3201612254 creator A5082185821 @default.
• W3201612254 date "2021-01-01" @default.
• W3201612254 modified "2023-10-18" @default.
• W3201612254 title "Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial" @default.
• W3201612254 cites W2000292756 @default.
• W3201612254 cites W2004306343 @default.
• W3201612254 cites W2035525224 @default.
• W3201612254 cites W2051563676 @default.
• W3201612254 cites W2053083499 @default.
• W3201612254 cites W2060281755 @default.
• W3201612254 cites W2074274108 @default.
• W3201612254 cites W2079150475 @default.
• W3201612254 cites W2096134439 @default.
• W3201612254 cites W2103789431 @default.
• W3201612254 cites W2105683151 @default.
• W3201612254 cites W2113818241 @default.
• W3201612254 cites W2119938514 @default.
• W3201612254 cites W2125447919 @default.
• W3201612254 cites W2143743735 @default.
• W3201612254 cites W2154200023 @default.
• W3201612254 cites W2155090369 @default.
• W3201612254 cites W2155492044 @default.
• W3201612254 cites W2156575195 @default.
• W3201612254 cites W2157769714 @default.
• W3201612254 cites W2160373161 @default.
• W3201612254 cites W2162731664 @default.
• W3201612254 cites W2163145856 @default.
• W3201612254 cites W2165741055 @default.
• W3201612254 cites W2168579528 @default.
• W3201612254 cites W2560322684 @default.
• W3201612254 cites W2594373254 @default.
• W3201612254 cites W2913729906 @default.
• W3201612254 cites W4244315786 @default.
• W3201612254 doi "https://doi.org/10.21147/j.issn.1000-9604.2021.04.06" @default.
• W3201612254 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8435824" @default.
• W3201612254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34584374" @default.
• W3201612254 hasPublicationYear "2021" @default.
• W3201612254 type Work @default.
• W3201612254 sameAs 3201612254 @default.
• W3201612254 citedByCount "5" @default.
• W3201612254 countsByYear W32016122542022 @default.
• W3201612254 countsByYear W32016122542023 @default.
• W3201612254 crossrefType "journal-article" @default.
• W3201612254 hasAuthorship W3201612254A5001864411 @default.
• W3201612254 hasAuthorship W3201612254A5006423482 @default.
• W3201612254 hasAuthorship W3201612254A5012853410 @default.
• W3201612254 hasAuthorship W3201612254A5018806880 @default.
• W3201612254 hasAuthorship W3201612254A5019246084 @default.
• W3201612254 hasAuthorship W3201612254A5038522283 @default.
• W3201612254 hasAuthorship W3201612254A5046597133 @default.
• W3201612254 hasAuthorship W3201612254A5051014138 @default.
• W3201612254 hasAuthorship W3201612254A5053506947 @default.
• W3201612254 hasAuthorship W3201612254A5058194639 @default.
• W3201612254 hasAuthorship W3201612254A5060856715 @default.
• W3201612254 hasAuthorship W3201612254A5063077563 @default.
• W3201612254 hasAuthorship W3201612254A5067643729 @default.
• W3201612254 hasAuthorship W3201612254A5071654004 @default.
• W3201612254 hasAuthorship W3201612254A5072727640 @default.
• W3201612254 hasAuthorship W3201612254A5082185821 @default.
• W3201612254 hasBestOaLocation W32016122541 @default.
• W3201612254 hasConcept C121608353 @default.
• W3201612254 hasConcept C126322002 @default.
• W3201612254 hasConcept C141071460 @default.
• W3201612254 hasConcept C143998085 @default.
• W3201612254 hasConcept C191897082 @default.
• W3201612254 hasConcept C192562407 @default.
• W3201612254 hasConcept C197934379 @default.
• W3201612254 hasConcept C23131810 @default.
• W3201612254 hasConcept C2776694085 @default.
• W3201612254 hasConcept C2777802072 @default.
• W3201612254 hasConcept C2778456384 @default.
• W3201612254 hasConcept C2778527123 @default.
• W3201612254 hasConcept C2908647359 @default.
• W3201612254 hasConcept C526805850 @default.
• W3201612254 hasConcept C71924100 @default.
• W3201612254 hasConcept C99454951 @default.
• W3201612254 hasConceptScore W3201612254C121608353 @default.
• W3201612254 hasConceptScore W3201612254C126322002 @default.
• W3201612254 hasConceptScore W3201612254C141071460 @default.
• W3201612254 hasConceptScore W3201612254C143998085 @default.
• W3201612254 hasConceptScore W3201612254C191897082 @default.

• next